Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (7277)	4/2/2005 11:26:52 AM
From: sandintoes	Respond to of 8752

Good I'm ready to make some money.

To: Vendit™ who wrote (7277)	4/2/2005 12:00:51 PM
From: sandintoes	Read Replies (1) \| Respond to of 8752

People To Watch The Week Ahead: April 4-8, 2005 Forbes.com staff, 04.02.05, 6:00 AM ET A look ahead to the week's doers and doings in business, entertainment and technology: Background on Balsillie The rumor mill is jumping with talk that a takeover of BlackBerry wireless e-mail device maker Research in Motion (nasdaq: RIMM - news - people ) is in the works. The company's stock climbed last week on new speculation that mobile phone giant Nokia (nyse: NOK - news - people ) might be interested in a purchase. Of course, RIM has been the object of takeover rumors before, and the company's $14.4 billion market capitalization would make it a very pricey purchase. Expect CEO James Balsillie to be asked about it when the company reports its fourth-quarter and fiscal 2005 earnings on Tuesday. Analysts expect the company to report a profit of 65 cents per share, up from 25 cents a year ago. --David M. Ewalt It's nice to know that Accenture (nyse: ACN - news - people ) practices what it preaches when it comes to boosting profits. On Thursday, William Green, chief executive of the world's largest management and consulting firm, is expected to report fiscal second-quarter earnings of 32 cents per share, up from the 29 cents a year ago. Accenture offers tips to global corporations in areas such as strategic planning, supply, personnel, planning and computer technology. --Scott Reeves Background on Green Background on McKinnell On Tuesday, Pfizer (nyse: PFE - news - people ) will host its long-awaited annual analyst meeting. Chief Executive Hank McKinnell and his team will detail the drug giant's plans now that the debate over the safety of its Cox-2 inhibitors, Celebrex and Bextra, is finally cooling down. Some analysts may try to divine how much risk there is to the patent for Lipitor, the $10 billion-per-year cholesterol drug that is Pfizer's biggest seller. Another big question could be about the drug giant's experimental pill to raise HDL, the "good cholesterol"--new data on the drug is expected next year. Also, analysts may pressure Pfizer on whether it might cut its sales force, ending a long-standing arms race with drug giants such as Merck (nyse: MRK - news - people ) and GlaxoSmithKline (nyse: GSK - news - people ), or, in an idea advanced by A.G. Edwards analyst Al Rauch, spin off its basic research labs to create biotech companies, which might generate more value for investors. Investors and analysts wait with bated breath--Pfizer shares have dropped more than 25% this year. --Matthew Herper forbes.com